Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Sutro Biopharma, Inc.NASDAQ: STRO

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $42.86M fell 50.1% year over year, behind the -32.3% change in trailing-twelve-month operating expenses. Sequentially, it fell 5.4% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.

Context

  • Operating expenses amounted to 195.3% of revenue in FY2025, down 277.4 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -50.1% toward the trailing-twelve-month pace of -32.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$42.86M-5.4% QoQ
Last fiscal yearDec 2025
$200.11M-31.8% YoY
LTMMar 2026
$213.41M-32.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-50.1%——
1 year-31.8%——
3-year CAGR+2.0%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
200.11M USD
Year-over-year change
-31.8%
4-year CAGR
+7.4%

Operating Expenses vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -32.3% is the 6th highest of 9, against a peer median of -21.8%.
  • Operating expenses amounts to 214.2% of revenue for STRO, versus a peer median of 48012.5%.
STRO Competitors
Operating Expenses for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$213.41M USD-32.3%+2.0%214.2%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$118.5M USD-49.4%+2.7%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$92.88M USD-4.0%+25.5%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$91.4M USD+21.9%+10.8%—
DTILPrecision BioSciences, Inc.LTM Mar 2026$82.81M USD-13.0%-1.4%183.7%
CNTBConnect Biopharma Holdings LimitedFY2025$58.14M USD+19.9%-21.3%90840.6%
STTKShattuck Labs, Inc.LTM Mar 2026$51.84M USD-32.4%+34.1%5184.4%
KLRSKalaris Therapeutics IncLTM Mar 2026$47.61M USD-33.8%+48.8%—
IFRXInflaRx N.V.LTM Mar 2026€35.14M EUR-30.5%+8.4%119798.7%
Peer median (excluding STRO) —-21.8%+9.6%48012.5%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.